Canada: Myriad Genetics Holding That CDNA Is Patent-Eligible Subject Matter Is Good News For Those Seeking Or Enforcing Patents For Computer-Implemented Technologies

Last Updated: October 1 2013
Article by Ian C. McMillan and Matthew Cahill (Summer Student)

On June 13, 2013, the Supreme Court of the United States issued its decision in the Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al. (Myriad). Although this decision concerns the validity of patent claims in biotechnology, it may be relevant to other fields where courts must often distinguish between patent eligible subject matter and "laws of nature, natural phenomena, and abstract ideas", which are not eligible for patent protection.  Our interest is in the implications of the Myriad decision for computer-implemented inventions, particularly when contrasted with the decision in Mayo Collaborative Services v. Prometheus Laboratories (Prometheus).

Where inventiveness lies entirely in mathematical algorithms, and not in the possibly routine steps of programming computers to implement them, Prometheus suggests that the corresponding patent claims would be invalid. However, we argue that Myriad has the opposite implication. By further blurring the test for patent eligible subject matter, the chances that such claims would be found valid has been improved, although the issue remains very much in doubt as  Myriad and Prometheus point to opposing results.

Laws of nature and natural phenomena

Myriad considered whether the claimed subject matter was ineligible for patent protection as a natural phenomenon ( summary and possible implications). Myriad Genetics Inc. (Myriad) obtained several patents after discovering the precise location and sequence of the human genes BRCA1 and BRCA2. The challenged claims covered "isolated DNA" corresponding to the BRCA genes as they exist in the chromosome as well as BRCA complementary-DNA (cDNA). In nature, genes are transcribed to produce messenger RNA (mRNA). Using well-established laboratory techniques, mRNA can be reverse-transcribed to yield cDNA.

With respect to the BRCA genes, the Supreme Court held that "a naturally occurring DNA segment is a product of nature, and not patent eligible merely because it has been isolated". The Court took a more favourable view of the claims related to BRCA cDNAs. They were of the view that "...the lab technician unquestionably creates something new when cDNA is made" and went on to conclude that claims to cDNA are patent eligible under § 101. This is notable because, once a gene of interest has been identified, synthesizing the corresponding cDNA is straightforward.

Prometheus ( summary) holds that a process that relies on unpatentable subject matter must "also contain other elements or a combination of elements, sometimes referred to as an 'inventive concept,' sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the natural law itself." These other elements, or combination of elements, must not be "obvious, already in use, or purely conventional". In Prometheus, the unpatentable subject matter was a law of nature, specifically the relationship between metabolite concentrations and the effectiveness or toxicity of a drug. The claimed process that incorporated this natural law – instructions for doctors to apply the relationship when treating patients – was not sufficient to "transform unpatentable natural correlations into patentable applications."

In Myriad, the unpatentable subject matter was a natural phenomenon, specifically the naturally occurring DNA corresponding to a BRCA gene. Simply isolating this DNA was, apparently, not sufficient to transform the otherwise patent ineligible subject matter into a patent eligible composition. However, cDNA was found to be patent eligible, despite being derived from ineligible subject matter using steps that are arguably "obvious, already in use or purely conventional".

Abstract Ideas

We cannot easily reconcile the need for "something more" in Prometheus with the Court's holding in Myriad with respect to cDNA. In Myriad, the Court did not seem concerned with "other elements" or an "inventive concept". They accepted that cDNA did not exist in nature and this sufficed to render it patent eligible. This may reflect a difference in how the Court approaches the various kinds of patent ineligible subject matter, though this was not stated explicitly.

The decision in Myriad arguably supports patent claims for computer-implementations of abstract ideas or mathematical algorithms. Programming a computer to execute a method according to a mathematical algorithm may be analogous to synthesizing cDNA corresponding to a known gene. The mathematical algorithm, like natural DNA, is not, on its own, eligible for patent protection. However, the computer configured to execute a method according to a mathematical algorithm is not a mere abstraction, and thus should not for that reason alone be ineligible for patent protection. What's more, programming a computer is arguably no more "obvious" or "purely conventional" than cDNA synthesis.

If computer-implemented subject matter is novel and inventive, then, following Myriad, it may well be patent eligible, even if a great deal of the novelty and inventiveness is a consequence of the underlying mathematical algorithm, just as the novelty and inventiveness of cDNA derives from the newly discovered DNA.  On the other hand, Prometheus suggests that such computer-implemented subject matter may not be patent eligible as the mere programming of a computer to implement the mathematical algorithm would likely be characterized in many cases as obvious or purely conventional. Additionally, the Supreme Court has expressed concern about patents that may pre-empt the use of mathematical algorithms in many fields. Thus, to have the best chance of being eligible for patent protection, a claim for a computer implementation of a mathematical algorithm should not cover all possible implementations of the mathematical algorithm, but instead should be limited to a particular application, and recite hardware relevant to that application.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Ian C. McMillan
Similar Articles
Relevancy Powered by MondaqAI
Blake, Cassels & Graydon LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Blake, Cassels & Graydon LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions